Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease
Source: View publication →
In patients with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation, targeted interleukin-6 inhibition with ziltivekimab profoundly lowered inflammatory biomarkers but failed to reduce the risk of major adverse cardiovascular events.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ZEUS trial represents a major null result for the inflammatory hypothesis in cardiovascular disease. Despite earlier successes with upstream therapies and ziltivekimab's profound ability to lower hs-CRP and free IL-6, it failed to reduce clinical events. This highlights a critical disconnect between the reduction of intermediate inflammatory biomarkers and hard clinical outcomes, suggesting that downstream IL-6 ligand inhibition may not provide cardiovascular risk reduction in patients with concurrent ASCVD and CKD.
Historical Context
The inflammatory hypothesis of atherothrombosis was validated by the 2017 CANTOS trial, which demonstrated that targeting IL-1β with canakinumab reduced cardiovascular events. Subsequent phase 2 data (the RESCUE trial) showed ziltivekimab potently lowered hs-CRP and other inflammatory markers in CKD patients. The ZEUS trial was designed to determine whether this targeted downstream IL-6 ligand inhibition would definitively reduce cardiovascular endpoints in a high-risk population with ASCVD, CKD, and residual inflammatory risk.
Guided Discussion
High-yield insights from every perspective
How does the failure of ziltivekimab to reduce MACE, despite profoundly lowering inflammatory biomarkers, challenge our understanding of the interleukin-1 beta to interleukin-6 to CRP inflammatory cascade in atherosclerosis?
Key Response
Students need to understand the CANTOS trial, where upstream IL-1b inhibition reduced MACE, versus this trial. IL-6 is downstream of IL-1b. The dissociation between lowering downstream biomarkers like CRP and clinical benefit suggests that either the specific pathway targeted, the degree of inhibition, or pleiotropic effects of upstream targets are more important for plaque stabilization than just lowering systemic CRP.
Given that ziltivekimab lowered inflammatory markers but not MACE in this population, how should this influence a clinicians decision to use hsCRP as a primary target for titrating medical therapy in patients with ASCVD and CKD?
Key Response
Residents often use biomarkers to guide therapy. This study highlights the concept of surrogate endpoint failure. It reinforces that while elevated hsCRP indicates risk, pharmacologically driving it down does not guarantee improved cardiovascular outcomes, reminding residents to prioritize proven therapies like statins and SGLT2 inhibitors over treating the biomarker itself.
Considering the specific inclusion of patients with chronic kidney disease, how might the uremic milieu and alternative inflammatory pathways in CKD explain the lack of MACE reduction with isolated IL-6 inhibition compared to earlier success seen in trials of patients with normal renal function?
Key Response
Fellows should appreciate phenotypic differences. CKD patients have complex, multifactorial cardiovascular risk, including vascular calcification, endothelial dysfunction, and uremic toxins. Inhibiting a single cytokine might be insufficient in this population due to competing risk factors and alternative inflammatory pathways driving non-atherothrombotic cardiovascular events.
How can we use the negative clinical outcome of this trial to teach junior colleagues about the danger of relying on surrogate biomarkers like hsCRP when evaluating the efficacy of novel cardiovascular therapies?
Key Response
Attendings must contextualize trial results. This trial serves as a classic teaching point on the difference between surrogate endpoints and hard clinical endpoints. It reminds the team that biological plausibility and biomarker reduction do not automatically translate to clinical efficacy, preventing premature adoption of unproven therapies based solely on lab values.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
What specific methodological designs or biomarker profiling approaches could be integrated into future trials to identify whether the lack of MACE reduction with ziltivekimab was due to insufficient target engagement at the tissue level, off-target effects, or simply selecting the wrong patient endotype?
Key Response
PhD researchers focus on mechanistic failure. Utilizing advanced proteomics, transcriptomics, or plaque imaging in a subset of trial participants could have elucidated whether systemic IL-6 inhibition translated to reduced local vascular inflammation, helping to distinguish between a failed mechanism of action and an unresponsive patient population.
When reviewing the manuscript, how heavily should we scrutinize the types of cardiovascular events that occurred, specifically looking for competing risks such as non-atherosclerotic cardiovascular death which are prevalent in the CKD population and may have diluted any potential benefit on classical atherosclerotic events?
Key Response
Editors must ensure the primary endpoint aligns with the mechanism. In a CKD cohort, patients often die from arrhythmias or heart failure rather than atherothrombotic myocardial infarction. If the composite MACE endpoint was heavily driven by non-atherothrombotic events, the trial might falsely conclude that IL-6 inhibition is ineffective for atherosclerosis, representing a crucial limitation that authors must transparently address.
In light of these negative findings for ziltivekimab, how should the ACC and AHA guidelines for the management of residual inflammatory risk in ASCVD be updated, particularly regarding the use of colchicine versus targeted cytokine inhibitors in patients with concurrent CKD?
Key Response
Guideline committees must synthesize conflicting evidence. Current guidelines give a Class 2b recommendation for low-dose colchicine for residual inflammation. The failure of ziltivekimab solidifies that expensive, targeted biologics should not be recommended outside of trials for this purpose, and cements broad-spectrum agents like colchicine as the only currently viable, guideline-directed anti-inflammatory approach for ASCVD, though CKD dosing restrictions remain a challenge.
Clinical Landscape
Noteworthy Related Trials
CANTOS Trial
Tested
Canakinumab (IL-1beta inhibitor)
Population
Patients with prior MI and hsCRP >= 2 mg/L
Comparator
Placebo
Endpoint
3-point MACE (CV death, nonfatal MI, nonfatal stroke)
CIRT Trial
Tested
Low-dose methotrexate
Population
Patients with prior MI or multivessel CAD plus T2DM or metabolic syndrome
Comparator
Placebo
Endpoint
Composite of nonfatal MI, nonfatal stroke, CV death, or urgent revascularization
COLCOT Trial
Tested
Colchicine 0.5 mg daily
Population
Patients within 30 days of a myocardial infarction
Comparator
Placebo
Endpoint
Composite of CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis